Sign in

CIK 0001609809

  • Non-accelerated filer
  • Smaller reporting company

Seres Therapeutics, Inc.

Sign in to watch
Ticker
MCRB
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
274326290
Phone
+1 617-945-9626
Business address
200 SIDNEY STREET, CAMBRIDGE, MA, 02139
Former names
Seres Therapeutics, Inc., Seres Health, Inc.
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$795
in 4 filings, $795 under 10b5-1 plans

Net −$795. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2024-02-16 Arkowitz David Chief Financial Officer Sale 10b5-1 −3,939 $1.08 $4K 182,442
2024-02-15 Arkowitz David Chief Financial Officer Exercise or conversion 10b5-1 +10,625 186,381
2024-02-15 Arkowitz David Chief Financial Officer Exercise or conversion · Restricted Stock Units 10b5-1 −10,625 31,875
2024-02-14 Arkowitz David Chief Financial Officer Grant or award · Stock Option (Right to Buy) 10b5-1 +213,750 213,750
2024-02-14 Arkowitz David Chief Financial Officer Grant or award · Stock Option (Right to Buy) 10b5-1 +287,905 287,905
2024-02-14 Arkowitz David Chief Financial Officer Grant or award · Restricted Stock Units 10b5-1 +35,625 35,625
2023-10-30 Arkowitz David Chief Financial Officer Sale 10b5-1 −4,066 $1.35 $5K 175,756
2023-10-27 Arkowitz David Chief Financial Officer Exercise or conversion 10b5-1 +13,209 179,822
2023-10-27 Arkowitz David Chief Financial Officer Exercise or conversion · Restricted Stock Units 10b5-1 −13,209 13,209
2023-04-27 Arkowitz David Chief Financial Officer Grant or award · Restricted Stock Units 10b5-1 +26,418 26,418
2023-04-27 Arkowitz David Chief Financial Officer Grant or award +42,500 166,613
2023-02-03 Arkowitz David Chief Financial Officer Grant or award · Restricted Stock Units +42,500 42,500
2023-02-03 Arkowitz David Chief Financial Officer Grant or award · Stock Option (Right to Buy) +85,000 85,000
2022-10-27 Arkowitz David Chief Financial Officer Grant or award +42,500 112,992
2022-07-05 Arkowitz David Chief Financial Officer Grant or award +63,492 $3.15 $200K 65,492
2022-06-15 Arkowitz David Chief Financial Officer Exercise or conversion +5,000 70,492
2022-06-15 Arkowitz David Chief Financial Officer Exercise or conversion · Restricted Stock Units −5,000 0
2022-02-04 Arkowitz David Grant or award · Stock Option (Right to Buy) +190,000 190,000
2021-06-01 Arkowitz David Chief Financial Officer Grant or award · Stock Options (right to buy) +270,000 270,000
2021-06-01 Arkowitz David Chief Financial Officer Grant or award · Restricted Stock Units +5,000 5,000

Page 1 of 1 · 20 trades